To ask the Secretary of State for Health, what assessment his Department has made on the likely incidence of recurrent respiratory papillomatosis in the event that the (a) quadrivalent vaccine is maintained for UK HPV vaccination programme for girls and (b) bivalent vaccine is introduced for the UK HPV vaccination programme for girls.
23 March 2016
The Department has not estimated the impact on the incidence of recurrent respiratory papillomatosis if the bivalent vaccine replaces the quadrivalent vaccine in the human papillomavirus (HPV) vaccination programme for girls.
Warwick University is carrying out some limited analysis, in the context of its modelling work on the impact and cost effectiveness of extending HPV vaccination to boys, but the results are academically and commercially confidential, and subject to review by the Joint Committee on Vaccination and Immunisation, the independent expert body that advises Ministers on immunisation matters.
Estimates of the potential impact of the HPV vaccination programme on cancer and warts, including the incidence of recurrent respiratory papillomatosis, have been previously published by Public Health England in the British Medical Journal in 2011: